Dr Axel Grothey and Dr Guillem Argiles will review key studies presented at the annual meeting on GI cancers in Barcelona and discuss the application of the data for clinical practice.
0.5 AMA PRA Category 1 Credit(s)™
Jul 12, 2019
Jul 12, 2020
- Guillem Argiles, MD, PhD, Vall d'hebron University, Barcelona, Spain
- Axel Grothey, MD, West Cancer Center, Memphis, Tennessee, United States
Abstract LBA-006: BEACON CRC: a randomized, 3-Arm, phase 3 study of encorafenib and cetuximab with or without binimetinib vs choice of either irinotecan or FOLFIRI plus cetuximab in BRAF V600E–mutant metastatic colorectal cancer
Abstract O-026: Results of REARRANGE trial: A randomized phase 2 study comparing different dosing approaches for regorafenib (REG) during the first cycle of treatment in patients (pts) with metastatic colorectal cancer (mCRC)
Abstract PD-029: Regorafenib dose escalations in the prospective, observational CORRELATE study in patients with metastatic colorectal cancer
Abstract PD-015: Clinical impact of neutropenia and febrile neutropenia in metastatic colorectal cancer patients treated with FOLFOXIRI/bevacizumab: a pooled analysis of TRIBE and TRIBE2 studies
Abstract PD-016: Health-related quality of life in RAS wild-type metastatic colorectal cancer patients treated with panitumumab plus FOLFOX followed by panitumumab or panitumumab plus 5-FU/LV maintenance: the secondary endpoint of the Valentino study
Abstract P-115: The onset of grade >= 3 neutropenia at the first cycle is associated with longer overall survival in metastatic colorectal cancer patients treated with trifluridine/tipiracil
Abstract SO-007: Regorafenib plus nivolumab in patients with advanced gastric (GC) or colorectal cancer (CRC): an open label, dose finding, and dose expansion Phase 1b trial (REGONIVO, EPOC1603)
Guillem Argiles, MD, PhDVall d'hebron University
Axel Grothey, MDWest Cancer Center
Memphis, Tennessee, United States
This educational activity is specifically designed for hematology/oncology specialists, gastroenterologists, oncology nurse practitioners, and other healthcare professionals who are involved or interested in the management of gastrointestinal cancers.
After successful completion of this educational activity, participants should be able to:
- Increase knowledge regarding therapies, including targeted therapies, utilized in the treatment of mCRC
- Gain greater competence related to optimizing dosing strategies or outcomes based on known side effects of therapies used in mCRC
This educational activity is supported by a grant from Bayer HealthCare Pharmaceuticals.
In support of improving patient care, this activity has been planned and implemented by the Postgraduate Institute for Medicine and prIME Oncology. Postgraduate Institute for Medicine is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.
The Postgraduate Institute for Medicine designates this enduring material for a maximum of 0.5 AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
This activity is jointly provided by Postgraduate Institute for Medicine and prIME Oncology.
Method of Participation
Estimated time to complete: 0.5 hour(s)
To contact Postgraduate Institute for Medicine please visit www.pimed.com.
Disclosure of Relevant Financial Relationships
Postgraduate Institute for Medicine (PIM) and prIME Oncology require instructors, planners, managers, and other individuals who are in a position to control the content of this activity to disclose any real or apparent conflict of interest (COI) they may have as related to the content of this activity. All identified COI are thoroughly vetted and resolved according to PIM policy. PIM is committed to providing its learners with high-quality activities and related materials that promote improvements or quality in healthcare and not a specific proprietary business interest of a commercial interest.
The faculty reported the following financial relationships or relationships to products or devices they or their spouses/life partners have with commercial interest related to the content of this activity:
Dr Argiles has disclosed that he has received consulting fees from Amgen, Bayer Healthcare Pharmaceuticals, Merck, Roche, and Servier. He has agreed to disclose any unlabeled/unapproved uses of drugs or products referenced in his presentation.
Dr Grothey has disclosed that he has received consulting fees from Array, Bayer Healthcare Pharmaceuticals, Bristol-Myers Squibb, Daiichi, Eisai, and Genentech. He has also performed contracted research for Array, Bayer Healthcare Pharmaceuticals, Eisai, and Genentech. He has agreed to disclose any unlabeled/unapproved uses of drugs or products referenced in his presentation.
Postgraduate Institute for Medicine planners and managers have disclosed no relevant financial relationships.
The employees of prIME Oncology have disclosed:
- Davecia RCameron, MS (Medical Education Director) – no relevant financial relationships
- Trudy Stoddert, ELS (editorial content reviewer) – worked on non–CME certified projects in the last 12 months supported by Array; AstraZeneca; F. Hoffmann-La Roche Ltd; Ipsen; Merck KGaA, Darmstadt, Germany; Pfizer; Servier; and Shire
- Susan McKinney (editorial content reviewer) – no relevant financial relationships
This activity has been peer reviewed and the reviewer has disclosed no relevant financial relationships.
Disclosure Regarding Unlabeled Use
This activity may contain discussion of published and/or investigational uses of agents that are not indicated by the US Food and Drug Administration or European Medicines Agency. Please refer to the official prescribing information for each product discussed for discussions of approved indications, contraindications, and warnings.
Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patients’ conditions and possible contraindications or dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities.